Nihon Medi-Physics Company, Limited

National Institutes for Quantum Science and Technology

National Hospital Organization

Sony Corporation

Olympus Corporation

Olympus Medical Systems Corporation

Saturn Licensing LLC

Tokyo Institute of Technology

Terumo Cardiovascular Systems Corporation

Hiroaki Ichikawa

Hiroshi Tanaka

Tsutomu Okada

Seiji Maeda

Naomi Sugimoto

Yasuhito Kura

Yoshio Onuki

Jun Ichinose

Takaaki Komiya

Kazuki Honda

Hideyuki Kasahara

Randal James Kadykowski

Kazushi Murakami

Tatsutoshi Hashimoto

Takehiro Nishiie

Kenichi Kikuchi

Yuki Okumura

Daisaku Nakamura

Akihito Kano

Yoshio Honda

Taku Ito

Kimio Hatajiri

Masato Kiriu

Susumu Komagata

Akihiro Shimazu

Yurie Fukui

Miho Ikenaga

Yoshifumi Maya

Yoshihiro Doi

Gota Tonoya

Mitsuhide Naruse

Akihiro Izawa

Hisashi Suzuki

Kotaro Nagatsu

Tomoyuki Imai

Hiroyuki Okudaira

A method for producing anAc solution includes a step (I) of irradiating aRa target with particles to generate two or more actinium radioisotopes (Ac) including at leastAc, a step (II) of dissolving theRa target after the aforementioned step to obtain a solution (1), a step (III) of separatingRa and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other thanAc to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex withAc, and a targeting agent.

Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution

Provided is a method for producing a radiohalogen-labeled compound, the method comprises: a step in which a radiohalogen-labeling precursor compound (S-L) having a leaving group (L) capable of being nucleophilically substituted by a radioactive halide ion (X) is subjected to a radiohalogenation reaction to obtain a reaction mixture RM1 which contains the radiohalogen-labeling precursor compound (S-L) and a reaction product (S&#x2014;X) resulting from the radiohalogenation reaction; a step in which the reaction mixture RM1 is mixed with a polyvalent acid or a salt thereof to obtain a reaction mixture RM2; and a step in which the reaction product (S&#x2014;X) is purified from the reaction mixture RM2 by a solid phase extraction method.

Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical

Provided are a compound represented by the following formula (1): wherein Xrepresents a hydrogen atom or a halogen atom, Xrepresents a fluorine atom or a nitrile group, and Xrepresents a radioactive halogen atom,

2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same

Growing community of inventors

Tokyo, Japan

Hiroaki Ichikawa